Physician profile
Jorge E Corso
NPI 1235314329
$18,463.27
in general payments reported to CMS, 2019-2025
29 companies · $7,979 in 2025
The $7,979 reported for 2025 was more than what 88% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $558 · 2021: $337 · 2022: $718 · 2023: $3,185 · 2024: $3,970 · 2025: $7,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,200 · Food and Beverage: $3,992 · Travel and Lodging: $3,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,200.00 |
| Food and Beverage | $3,992.19 |
| Travel and Lodging | $3,940.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $11,644.23 | 2019-2025 | Torus Stent Graft System, Endocross Device, Alto Abdominal Stent Graft System |
| Abbott Laboratories | $2,513.43 | 2023-2025 | Acculink, Xact, Esprit |
| Bard Peripheral Vascular, INC. | $1,045.71 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $749.90 | 2019-2025 | Gore Tag Thoracic Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Tag Conformable Thoracic Endoprosthesis |
| Medtronic, INC. | $367.83 | 2021-2025 | Hawkone, In.Pact Admiral, Endurant Iis |
| Silk Road Medical, INC. | $322.97 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Penumbra, INC. | $303.08 | 2019-2025 | Indigo System |
| Medtronic Vascular, INC. | $281.21 | 2019-2020 | |
| Reflow Medical INC | $231.70 | 2025 | |
| Boston Scientific Corporation | $166.26 | 2021-2025 | Enroute Transcarotid Neuroprotection System |
| Bolton Medical INC | $146.52 | 2020 | |
| Cook Medical LLC | $137.04 | 2020-2023 | Cook |
| Shockwave Medical, INC | $105.14 | 2025 | |
| Janssen Pharmaceuticals, INC | $89.40 | 2019-2023 | Xarelto |
| Amgen INC. | $69.47 | 2019-2023 | Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $46.69 | 2021-2023 | Saber |
| Pfizer INC. | $30.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.77 | 2019-2021 | |
| Cardiva Medical, INC. | $24.36 | 2024 | Cardiva Vascade 6/7f Vcs |
| Baxter Healthcare | $22.85 | 2023 | Coseal |
| Davol INC. | $21.34 | 2022 | |
| Atricure, INC. | $20.30 | 2023 | |
| Sanofi-Aventis U.S. LLC | $20.12 | 2023 | |
| Sirtex Medical INC | $15.72 | 2025 | Lava Les (Liquid Embolic System) |
| Astellas Pharma US INC | $15.65 | 2019 | |
| Becton, Dickinson and Company | $15.52 | 2024 | Rotarexs 6 F X 135 Cm |
| Ekos Corporation | $15.17 | 2019 | |
| Terumo Medical Corporation | $11.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Corso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.